While the red-hot biotech initial public offering (IPO) market has grabbed headlines over the past year, tech companies that service these businesses have also cashed in. IMS Health signaled its intent to hop aboard the bandwagon at the start of the year, and it is now reportedly weeks away from going public.
When IBM was preparing its artificial-intelligence program Watson to compete on the game show "Jeopardy!," it made the system read Wikipedia. The training worked and Watson beat its human competitors. Now IBM and the New York Genome Center are testing whether making Watson read PubMed can help defeat cancer.
Illumina released a pricing structure for its BaseSpace genomics cloud platform back in July 2012 but decided to hold off on actually charging users for the service. Since then, BaseSpace's user base has swelled to more than 12,000 people, with 2,000 of them logging on each week. Now the sequencing giant is readying to activate its payment model.
Clinical trials have increased in complexity over the past decade, with sponsors working with an increasing number of sites, countries and service providers. These massive globalized studies place new strains on the organization of essential study documents, collectively known as the trial master file.
As the scale of the National Cancer Institute's projects grows, downloading results for analysis on local systems becomes impractical. Recognizing this, NCI has allocated $20 million for cloud-based genomics pilot projects.
The scale of genomics sequencing projects continues to grow rapidly. Just as the 1,000 Genomes Project once dwarfed the Human Genome Project, now an initiative involving Amazon, Baylor College of Medicine and DNAnexus has surpassed both of them, generating 430 terabytes of data in the process.
CSC, known in Britain for its role in a health IT fiasco, has helped pharmaceutical distributors and other companies migrate to the cloud.
Veeva Systems has filed paperwork as expected to raise up to $150 million in an initial public offering. The fast-growing provider of cloud-based software for sales groups in life sciences would like to list its shares on the New York Stock Exchange under the symbol "VEEV."
In an InformationWeek profile, GlaxoSmithKline touts the benefits of a new online collaboration system, including the savings on travel expenses and satisfaction of the pharma giant's customers.
Accelrys ($ACCL) has added to a string of acquisitions in recent years with the buyout of ChemSW, a provider of software for companies in pharma and other sectors to ditch paper-based systems for managing chemical inventories.